Veru (VERU) Change in Accured Expenses (2015 - 2026)
Veru (VERU) posted quarterly Change in Accured Expenses of -$2.3 million for Q1 2026, down 143.88% year-over-year from $5.2 million in Q1 2025, and down 344.12% quarter-over-quarter from $942206.0 in Q4 2025.
Veru (VERU) Change in Accured Expenses (2015 - 2026) Analysis & Trends
Veru (VERU) has reported Change in Accured Expenses for 12 consecutive years, with -$2.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 143.88% year-over-year to -$2.3 million; the TTM figure through Mar 2026 stood at -$119017.0 (up 86.4% YoY), while the FY2025 annual figure was -$1.3 million, down 134.16% from the prior year.
- Change in Accured Expenses retreated to -$2.3 million in Q1 2026 per VERU's latest filing, from $942206.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $8.4 million in Q4 2022 and bottomed at -$9.3 million in Q1 2023.
- Historically, Change in Accured Expenses has averaged $32207.8 across 5 years, with a median of $530319.0 in 2024.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses jumped 1356.89% — and 2023, when it slumped 7884.04%.
- Veru's Change in Accured Expenses stood at $8.4 million in 2022, then plunged by 84.52% to $1.3 million in 2023, then sank by 226.84% to -$1.6 million in 2024, then surged by 157.34% to $942206.0 in 2025, then sank by 344.12% to -$2.3 million in 2026.
- Business Quant data shows VERU's Change in Accured Expenses at -$2.3 million in Q1 2026, $942206.0 in Q4 2025, and $514877.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Veru | 60.85 Mn | 35.06 Mn | - | 1.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.03 Mn |
| Jun 30, 2026 | 1.03 Mn |
| Mar 31, 2026 | -2.30 Mn |
| Mar 31, 2026 | -2.30 Mn |
| Dec 31, 2025 | 942,206.00 |
| Dec 31, 2025 | 942,206.00 |
| Sep 30, 2025 | 514,877.00 |
| Sep 30, 2025 | 514,877.00 |
| Jun 30, 2025 | 723,996.00 |
| Jun 30, 2025 | 723,996.00 |
| Mar 31, 2025 | -943,138.00 |
| Mar 31, 2025 | -943,138.00 |
| Dec 31, 2024 | -1.64 Mn |
| Dec 31, 2024 | -1.64 Mn |
| Sep 30, 2024 | 1.18 Mn |
| Sep 30, 2024 | 1.18 Mn |
| Jun 30, 2024 | 530,319.00 |
| Jun 30, 2024 | 530,319.00 |
| Mar 31, 2024 | 937,763.00 |
| Mar 31, 2024 | 937,763.00 |